AVX70561, an innovative immunotherapy for treatment of persistent HPV-infection - Lien Van Eyck, AstriVax Therapeutics

Despite effective vaccines, about 4% of individuals still carry high-risk HPV types 16 and 18, linked to cervical and head and neck cancers. AstriVax Therapeutics is developing an immunotherapy to trigger CD8+ T-cell responses, aiming to clear persistent infections and prevent pre-cancerous lesions.